The global Drugs for Brucellosis market was valued at million in 2024 and is projected to reach US$ million by 2032, at a CAGR of %during the forecast period.
Brucellosis is a bacterial infection caused by various species of the Brucella bacteria, primarily Brucella melitensis, Brucella abortus, and Brucella suis. The treatment of brucellosis typically involves the use of antibiotics.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
We have surveyed the Drugs for Brucellosis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Drugs for Brucellosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Brucellosis. This report contains market size and forecasts of Drugs for Brucellosis in global, including the following market information:
Global Drugs for Brucellosis market revenue, 2020-2025, 2026-2032, ($ millions)
Global top five Drugs for Brucellosis companies in 2024 (%)
Total Market by Segment:
Global Drugs for Brucellosis market, by Type, 2020-2025, 2026-2032 ($ millions)
Global Drugs for Brucellosis market segment percentages, by Type, 2024 (%)
Oral
Injection
Global Drugs for Brucellosis market, by Application, 2020-2025, 2026-2032 ($ millions)
Global Drugs for Brucellosis market segment percentages, by Application, 2024 (%)
Hospital
Pharmacy
Others
Global Drugs for Brucellosis market, by region and country, 2020-2025, 2026-2032 ($ millions)
Global Drugs for Brucellosis market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Brucellosis revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Drugs for Brucellosis revenues share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer Inc.
Bayer
Huvepharma
OraPharma,Inc.
Merck & Co.Inc.
RempexPharmaceuticals,Inc.
ZeotisInc.
BoehringerIngelheim International GmbH.
Elanco
Virabc Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Brucellosis, market overview.
Chapter 2: Global Drugs for Brucellosis market size in revenue.
Chapter 3: Detailed analysis of Drugs for Brucellosis company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Brucellosis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Brucellosis Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global Drugs for Brucellosis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Brucellosis Overall Market Size
2.1 Global Drugs for Brucellosis Market Size: 2024 VS 2032
2.2 Global Drugs for Brucellosis Market Size, Prospects & Forecasts: 2020-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs for Brucellosis Players in Global Market
3.2 Top Global Drugs for Brucellosis Companies Ranked by Revenue
3.3 Global Drugs for Brucellosis Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Brucellosis Companies in Global Market, by Revenue in 2024
3.5 Global Companies Drugs for Brucellosis Product Type
3.6 Tier 1, Tier 2, and Tier 3 Drugs for Brucellosis Players in Global Market
3.6.1 List of Global Tier 1 Drugs for Brucellosis Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs for Brucellosis Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global Drugs for Brucellosis Market Size Markets, 2024 & 2032
4.1.2 Oral
4.1.3 Injection
4.2 Segmentation by Type - Global Drugs for Brucellosis Revenue & Forecasts
4.2.1 Segmentation by Type - Global Drugs for Brucellosis Revenue, 2020-2025
4.2.2 Segmentation by Type - Global Drugs for Brucellosis Revenue, 2026-2032
4.2.3 Segmentation by Type - Global Drugs for Brucellosis Revenue Market Share, 2020-2032
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global Drugs for Brucellosis Market Size, 2024 & 2032
5.1.2 Hospital
5.1.3 Pharmacy
5.1.4 Others
5.2 Segmentation by Application - Global Drugs for Brucellosis Revenue & Forecasts
5.2.1 Segmentation by Application - Global Drugs for Brucellosis Revenue, 2020-2025
5.2.2 Segmentation by Application - Global Drugs for Brucellosis Revenue, 2026-2032
5.2.3 Segmentation by Application - Global Drugs for Brucellosis Revenue Market Share, 2020-2032
6 Sights by Region
6.1 By Region - Global Drugs for Brucellosis Market Size, 2024 & 2032
6.2 By Region - Global Drugs for Brucellosis Revenue & Forecasts
6.2.1 By Region - Global Drugs for Brucellosis Revenue, 2020-2025
6.2.2 By Region - Global Drugs for Brucellosis Revenue, 2026-2032
6.2.3 By Region - Global Drugs for Brucellosis Revenue Market Share, 2020-2032
6.3 North America
6.3.1 By Country - North America Drugs for Brucellosis Revenue, 2020-2032
6.3.2 United States Drugs for Brucellosis Market Size, 2020-2032
6.3.3 Canada Drugs for Brucellosis Market Size, 2020-2032
6.3.4 Mexico Drugs for Brucellosis Market Size, 2020-2032
6.4 Europe
6.4.1 By Country - Europe Drugs for Brucellosis Revenue, 2020-2032
6.4.2 Germany Drugs for Brucellosis Market Size, 2020-2032
6.4.3 France Drugs for Brucellosis Market Size, 2020-2032
6.4.4 U.K. Drugs for Brucellosis Market Size, 2020-2032
6.4.5 Italy Drugs for Brucellosis Market Size, 2020-2032
6.4.6 Russia Drugs for Brucellosis Market Size, 2020-2032
6.4.7 Nordic Countries Drugs for Brucellosis Market Size, 2020-2032
6.4.8 Benelux Drugs for Brucellosis Market Size, 2020-2032
6.5 Asia
6.5.1 By Region - Asia Drugs for Brucellosis Revenue, 2020-2032
6.5.2 China Drugs for Brucellosis Market Size, 2020-2032
6.5.3 Japan Drugs for Brucellosis Market Size, 2020-2032
6.5.4 South Korea Drugs for Brucellosis Market Size, 2020-2032
6.5.5 Southeast Asia Drugs for Brucellosis Market Size, 2020-2032
6.5.6 India Drugs for Brucellosis Market Size, 2020-2032
6.6 South America
6.6.1 By Country - South America Drugs for Brucellosis Revenue, 2020-2032
6.6.2 Brazil Drugs for Brucellosis Market Size, 2020-2032
6.6.3 Argentina Drugs for Brucellosis Market Size, 2020-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drugs for Brucellosis Revenue, 2020-2032
6.7.2 Turkey Drugs for Brucellosis Market Size, 2020-2032
6.7.3 Israel Drugs for Brucellosis Market Size, 2020-2032
6.7.4 Saudi Arabia Drugs for Brucellosis Market Size, 2020-2032
6.7.5 UAE Drugs for Brucellosis Market Size, 2020-2032
7 Companies Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Corporate Summary
7.1.2 Pfizer Inc. Business Overview
7.1.3 Pfizer Inc. Drugs for Brucellosis Major Product Offerings
7.1.4 Pfizer Inc. Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.1.5 Pfizer Inc. Key News & Latest Developments
7.2 Bayer
7.2.1 Bayer Corporate Summary
7.2.2 Bayer Business Overview
7.2.3 Bayer Drugs for Brucellosis Major Product Offerings
7.2.4 Bayer Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.2.5 Bayer Key News & Latest Developments
7.3 Huvepharma
7.3.1 Huvepharma Corporate Summary
7.3.2 Huvepharma Business Overview
7.3.3 Huvepharma Drugs for Brucellosis Major Product Offerings
7.3.4 Huvepharma Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.3.5 Huvepharma Key News & Latest Developments
7.4 OraPharma,Inc.
7.4.1 OraPharma,Inc. Corporate Summary
7.4.2 OraPharma,Inc. Business Overview
7.4.3 OraPharma,Inc. Drugs for Brucellosis Major Product Offerings
7.4.4 OraPharma,Inc. Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.4.5 OraPharma,Inc. Key News & Latest Developments
7.5 Merck & Co.Inc.
7.5.1 Merck & Co.Inc. Corporate Summary
7.5.2 Merck & Co.Inc. Business Overview
7.5.3 Merck & Co.Inc. Drugs for Brucellosis Major Product Offerings
7.5.4 Merck & Co.Inc. Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.5.5 Merck & Co.Inc. Key News & Latest Developments
7.6 RempexPharmaceuticals,Inc.
7.6.1 RempexPharmaceuticals,Inc. Corporate Summary
7.6.2 RempexPharmaceuticals,Inc. Business Overview
7.6.3 RempexPharmaceuticals,Inc. Drugs for Brucellosis Major Product Offerings
7.6.4 RempexPharmaceuticals,Inc. Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.6.5 RempexPharmaceuticals,Inc. Key News & Latest Developments
7.7 ZeotisInc.
7.7.1 ZeotisInc. Corporate Summary
7.7.2 ZeotisInc. Business Overview
7.7.3 ZeotisInc. Drugs for Brucellosis Major Product Offerings
7.7.4 ZeotisInc. Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.7.5 ZeotisInc. Key News & Latest Developments
7.8 BoehringerIngelheim International GmbH.
7.8.1 BoehringerIngelheim International GmbH. Corporate Summary
7.8.2 BoehringerIngelheim International GmbH. Business Overview
7.8.3 BoehringerIngelheim International GmbH. Drugs for Brucellosis Major Product Offerings
7.8.4 BoehringerIngelheim International GmbH. Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.8.5 BoehringerIngelheim International GmbH. Key News & Latest Developments
7.9 Elanco
7.9.1 Elanco Corporate Summary
7.9.2 Elanco Business Overview
7.9.3 Elanco Drugs for Brucellosis Major Product Offerings
7.9.4 Elanco Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.9.5 Elanco Key News & Latest Developments
7.10 Virabc Inc.
7.10.1 Virabc Inc. Corporate Summary
7.10.2 Virabc Inc. Business Overview
7.10.3 Virabc Inc. Drugs for Brucellosis Major Product Offerings
7.10.4 Virabc Inc. Drugs for Brucellosis Revenue in Global Market (2020-2025)
7.10.5 Virabc Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Drugs for Brucellosis Market Opportunities & Trends in Global Market
Table 2. Drugs for Brucellosis Market Drivers in Global Market
Table 3. Drugs for Brucellosis Market Restraints in Global Market
Table 4. Key Players of Drugs for Brucellosis in Global Market
Table 5. Top Drugs for Brucellosis Players in Global Market, Ranking by Revenue (2024)
Table 6. Global Drugs for Brucellosis Revenue by Companies, (US$, Mn), 2020-2025
Table 7. Global Drugs for Brucellosis Revenue Share by Companies, 2020-2025
Table 8. Global Companies Drugs for Brucellosis Product Type
Table 9. List of Global Tier 1 Drugs for Brucellosis Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Brucellosis Companies, Revenue (US$, Mn) in 2024 and Market Share
Table 11. Segmentation by Type � Global Drugs for Brucellosis Revenue, (US$, Mn), 2024 & 2032
Table 12. Segmentation by Type - Global Drugs for Brucellosis Revenue (US$, Mn), 2020-2025
Table 13. Segmentation by Type - Global Drugs for Brucellosis Revenue (US$, Mn), 2026-2032
Table 14. Segmentation by Application� Global Drugs for Brucellosis Revenue, (US$, Mn), 2024 & 2032
Table 15. Segmentation by Application - Global Drugs for Brucellosis Revenue, (US$, Mn), 2020-2025
Table 16. Segmentation by Application - Global Drugs for Brucellosis Revenue, (US$, Mn), 2026-2032
Table 17. By Region� Global Drugs for Brucellosis Revenue, (US$, Mn), 2024 & 2032
Table 18. By Region - Global Drugs for Brucellosis Revenue, (US$, Mn), 2020-2025
Table 19. By Region - Global Drugs for Brucellosis Revenue, (US$, Mn), 2026-2032
Table 20. By Country - North America Drugs for Brucellosis Revenue, (US$, Mn), 2020-2025
Table 21. By Country - North America Drugs for Brucellosis Revenue, (US$, Mn), 2026-2032
Table 22. By Country - Europe Drugs for Brucellosis Revenue, (US$, Mn), 2020-2025
Table 23. By Country - Europe Drugs for Brucellosis Revenue, (US$, Mn), 2026-2032
Table 24. By Region - Asia Drugs for Brucellosis Revenue, (US$, Mn), 2020-2025
Table 25. By Region - Asia Drugs for Brucellosis Revenue, (US$, Mn), 2026-2032
Table 26. By Country - South America Drugs for Brucellosis Revenue, (US$, Mn), 2020-2025
Table 27. By Country - South America Drugs for Brucellosis Revenue, (US$, Mn), 2026-2032
Table 28. By Country - Middle East & Africa Drugs for Brucellosis Revenue, (US$, Mn), 2020-2025
Table 29. By Country - Middle East & Africa Drugs for Brucellosis Revenue, (US$, Mn), 2026-2032
Table 30. Pfizer Inc. Corporate Summary
Table 31. Pfizer Inc. Drugs for Brucellosis Product Offerings
Table 32. Pfizer Inc. Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 33. Pfizer Inc. Key News & Latest Developments
Table 34. Bayer Corporate Summary
Table 35. Bayer Drugs for Brucellosis Product Offerings
Table 36. Bayer Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 37. Bayer Key News & Latest Developments
Table 38. Huvepharma Corporate Summary
Table 39. Huvepharma Drugs for Brucellosis Product Offerings
Table 40. Huvepharma Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 41. Huvepharma Key News & Latest Developments
Table 42. OraPharma,Inc. Corporate Summary
Table 43. OraPharma,Inc. Drugs for Brucellosis Product Offerings
Table 44. OraPharma,Inc. Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 45. OraPharma,Inc. Key News & Latest Developments
Table 46. Merck & Co.Inc. Corporate Summary
Table 47. Merck & Co.Inc. Drugs for Brucellosis Product Offerings
Table 48. Merck & Co.Inc. Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 49. Merck & Co.Inc. Key News & Latest Developments
Table 50. RempexPharmaceuticals,Inc. Corporate Summary
Table 51. RempexPharmaceuticals,Inc. Drugs for Brucellosis Product Offerings
Table 52. RempexPharmaceuticals,Inc. Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 53. RempexPharmaceuticals,Inc. Key News & Latest Developments
Table 54. ZeotisInc. Corporate Summary
Table 55. ZeotisInc. Drugs for Brucellosis Product Offerings
Table 56. ZeotisInc. Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 57. ZeotisInc. Key News & Latest Developments
Table 58. BoehringerIngelheim International GmbH. Corporate Summary
Table 59. BoehringerIngelheim International GmbH. Drugs for Brucellosis Product Offerings
Table 60. BoehringerIngelheim International GmbH. Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 61. BoehringerIngelheim International GmbH. Key News & Latest Developments
Table 62. Elanco Corporate Summary
Table 63. Elanco Drugs for Brucellosis Product Offerings
Table 64. Elanco Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 65. Elanco Key News & Latest Developments
Table 66. Virabc Inc. Corporate Summary
Table 67. Virabc Inc. Drugs for Brucellosis Product Offerings
Table 68. Virabc Inc. Drugs for Brucellosis Revenue (US$, Mn) & (2020-2025)
Table 69. Virabc Inc. Key News & Latest Developments
List of Figures
Figure 1. Drugs for Brucellosis Product Picture
Figure 2. Drugs for Brucellosis Segment by Type in 2024
Figure 3. Drugs for Brucellosis Segment by Application in 2024
Figure 4. Global Drugs for Brucellosis Market Overview: 2024
Figure 5. Key Caveats
Figure 6. Global Drugs for Brucellosis Market Size: 2024 VS 2032 (US$, Mn)
Figure 7. Global Drugs for Brucellosis Revenue: 2020-2032 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by Drugs for Brucellosis Revenue in 2024
Figure 9. Segmentation by Type � Global Drugs for Brucellosis Revenue, (US$, Mn), 2024 & 2032
Figure 10. Segmentation by Type - Global Drugs for Brucellosis Revenue Market Share, 2020-2032
Figure 11. Segmentation by Application � Global Drugs for Brucellosis Revenue, (US$, Mn), 2024 & 2032
Figure 12. Segmentation by Application - Global Drugs for Brucellosis Revenue Market Share, 2020-2032
Figure 13. By Region - Global Drugs for Brucellosis Revenue Market Share, 2020-2032
Figure 14. By Country - North America Drugs for Brucellosis Revenue Market Share, 2020-2032
Figure 15. United States Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 16. Canada Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 17. Mexico Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 18. By Country - Europe Drugs for Brucellosis Revenue Market Share, 2020-2032
Figure 19. Germany Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 20. France Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 21. U.K. Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 22. Italy Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 23. Russia Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 24. Nordic Countries Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 25. Benelux Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 26. By Region - Asia Drugs for Brucellosis Revenue Market Share, 2020-2032
Figure 27. China Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 28. Japan Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 29. South Korea Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 30. Southeast Asia Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 31. India Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 32. By Country - South America Drugs for Brucellosis Revenue Market Share, 2020-2032
Figure 33. Brazil Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 34. Argentina Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 35. By Country - Middle East & Africa Drugs for Brucellosis Revenue Market Share, 2020-2032
Figure 36. Turkey Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 37. Israel Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 38. Saudi Arabia Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 39. UAE Drugs for Brucellosis Revenue, (US$, Mn), 2020-2032
Figure 40. Pfizer Inc. Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 41. Bayer Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 42. Huvepharma Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 43. OraPharma,Inc. Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 44. Merck & Co.Inc. Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 45. RempexPharmaceuticals,Inc. Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 46. ZeotisInc. Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 47. BoehringerIngelheim International GmbH. Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 48. Elanco Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
Figure 49. Virabc Inc. Drugs for Brucellosis Revenue Year Over Year Growth (US$, Mn) & (2020-2025)
